Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. The objective of this study is to determine the efficacy of soquelitinib in reducing spleen volume or target lymph node volume in people with ALPS-FAS.

A drug approved to treat certain autoimmune diseases and cancers successfully alleviated symptoms of a rare genetic syndrome called autoimmune polyendocrine syndrome type 1 (APS-1).

Researchers involved with the NIAID Clinical Genomics Program study many diseases of the immune system that are rare and not well understood but that often shed light on basic immune function and more common immune disorders. This research is carried out across multiple labs, disease processes, and with many different tools.

The NIAID Clinical Genomics Program centralizes resources to be used for genomics and related research.

The Primary Immunodeficiency (PI) Diseases Registry at US Immunodeficiency Network (USIDNET) collects validated data on all PI diagnoses from patients who give Informed Consent. The de-identified data in the registry is freely disseminated to those with research questions about PI diseases.

The USIDNET Cell Repository, part of the US Immunodeficiency Network (USIDNET), provides a resource of DNA and functional lymphoid cells obtained from patients with various primary immunodeficiency diseases.

The STAT3base contains a listing of STAT3 mutations in human HIES identified in the Laboratory of Clinical Immunology and Microbiology as well as those published in the literature.

The NIAID FUNGI study about unexplained invasive fungal infections or APECED syndrome in adults and children is seeking study participants.